---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-245206"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:01:51.003821+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Viridian expects ~$490.9M cash as of Sept 30, 2025; preliminary, unaudited

## Summary
- Preliminary cash, equivalents, and marketable securities of ~$490.9M as of September 30, 2025.
- Figure is unaudited and may materially differ from final Q3 2025 balance sheet upon close.
- Full Q3 2025 financial results not yet finalized; no revenue or EPS guidance provided.
- Disclosure intended to provide early liquidity visibility ahead of complete financial report.

## SEC filing metadata
- accession: 0001193125-25-245206
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525245206/0001193125-25-245206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525245206/d12120d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-245206
- JSON: https://secwatch.observer/filing/0001193125-25-245206.json
- Plain text: https://secwatch.observer/filing/0001193125-25-245206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.